Galimedix Therapeutics Overview
Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta plays a role, such as in dry AMD, glaucoma and Alzheimer’s disease: Galimedix’s initial areas of focus. Its amyloid beta-targeting approach is strongly supported by our license deal with a major ophthalmology player, as well as recent successes in the field of Alzheimer’s disease. Galimedix’s approach blocks a key step in the neurodegenerative process with a highly specific, well tolerated small molecule without impacting normal neuronal function. This key step – the formation of toxic oligomers and protofibrils of amyloid beta (Aβ) – has emerged as a central cause of neurodegeneration. This understanding is supported by recent approvals and by positive late-stage clinical results with Aβ-targeting therapies for Alzheimer’s disease, as well as numerous publications about the role of Aβ in dry AMD and glaucoma.
Cumulative Funding Raised Over Time ($)
$2.0MJan 2019
Latest News
growth-positive
Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics, Inc. has announced encouraging data for its orally available small molecule GAL-201, which has shown potential in models of Alzheimer’s disease (AD). The molecule belongs to a new pharmacological class of amyloid beta aggregation modulators that act upstream of other known Aβ-targeting agents. The data was presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2024: advances in science and therapy). The next step for Galimedix is to move GAL-201 towards IND submission and clinical development.
Investment
growth-positive
Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model to be presented at AD/PD™ 2024 Conference | Corporate - EQS News
Galimedix Therapeutics, a Phase 2 clinical-stage biotechnology company, has announced the presentation of new pre-clinical data with GAL-201, a small molecule designed to target amyloid beta (Aβ) and suppress the formation of toxic Aβ aggregates in the brains of people with Alzheimer’s disease (AD). The data will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2024) in Lisbon, Portugal. The data shows the beneficial effects of GAL-201 in a transgenic mouse model of AD, indicating its potential as a treatment for AD.
Investment
growth-positive
Galimedix Therapeutics, Inc.'s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen's Aducanumab
Galimedix Therapeutics, Inc. announced that the recent positive results of a Phase 3 study in Alzheimer’s disease with Biogen’s aducanumab also validate the target of the company’s lead molecule, GAL-101. GAL-101 has the advantage of being a small molecule and blocks the formation of all forms of toxic oligomers at source while the antibody eliminates them only after their formation. Galimedix considers the recently announced aducanumab results in Alzheimer’s disease to be validation for GAL-101 eyedrops, which target the same amyloid beta pathology in dry macular degeneration (AMD) and glaucoma. The company is developing a Phase 2 program in these two indications using GAL-101 eyedrops. An additional oral formulation of GAL-101 is also in development for Alzheimers disease.
PartnersInvestment
growth-positive
Preclinical Studies Demonstrate Galimedix Therapeutics' Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models
Galimedix Therapeutics, a company developing solutions for ophthalmic and neurodegenerative diseases, has presented data showing that its investigational compound GAL-101 provides neuroprotection from misfolded amyloid beta molecules. The compound may also provide sustained detoxification. The data was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The companys Chief Scientific Officer, Dr. Hermann Russ, commented that the unique mechanism of GAL-101 has been shown to reduce the levels of amyloid beta present in the retina, thereby preventing neurodegeneration and increasing the chances of preventing vision loss.
InvestmentExpand
growth-positive
Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference
Galimedix Therapeutics presented an overview of data on its compound GAL-101, which has shown potential in preventing the formation of toxic amyloid beta oligomers in ophthalmic diseases. The company also presented positive safety and tolerability data from its Phase 1 study. GAL-101 was shown to reach the retina quickly and have a sustained effect for weeks. Galimedix is currently planning and fundraising for a Phase 2 program. The company is a phase 2 ophthalmic pharmaceutical company with a novel drug addressing glaucoma and dry AMD using an eye drops delivery platform.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2M |
| Last funding | $2M |
| Stage | Seed |
| Rounds | 1 |
| Investors | 2 |
Team Members
6
Employees: 1-10
Web & Social Links
| Website | galimedix.com |
Locations
Shorashim, Israel
3704 Calvend Lane, Kensington, MD, USA
Photos & Videos
No files yet
Galimedix Therapeutics Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsMoleculesTags (9)
brain-disorderdrug-deliveryophthalmologyvisually-impairedeye-diseasesglaucomadrug-discoveryalzheimers-diseasedegenerative-diseasesGalimedix Therapeutics Financials
$2M
Total funding
Undisclosed
Capital raised
$2M
Last funding
Seed
Funding stage
1
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$2.0MJan 2019
Private Equity Funding
Seed
Jan 2019
$2M
InFocus Capital Partners, Rimonci Capital
Galimedix Therapeutics Lifecycle
Cumulative Funding Raised Over Time
$2.0MJan 2019
All Events
Seed
Jan 2019
$2M
InFocus Capital Partners, Rimonci Capital
Galimedix Therapeutics News
7 articles
growth-positive
Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics, Inc. has announced encouraging data for its orally available small molecule GAL-201, which has shown potential in models of Alzheimer’s disease (AD). The molecule belongs to a new pharmacological class of amyloid beta aggregation modulators that act upstream of other known Aβ-targeting agents. The data was presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2024: advances in science and therapy). The next step for Galimedix is to move GAL-201 towards IND submission and clinical development.
Investment
growth-positive
Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model to be presented at AD/PD™ 2024 Conference | Corporate - EQS News
Galimedix Therapeutics, a Phase 2 clinical-stage biotechnology company, has announced the presentation of new pre-clinical data with GAL-201, a small molecule designed to target amyloid beta (Aβ) and suppress the formation of toxic Aβ aggregates in the brains of people with Alzheimer’s disease (AD). The data will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2024) in Lisbon, Portugal. The data shows the beneficial effects of GAL-201 in a transgenic mouse model of AD, indicating its potential as a treatment for AD.
Investment
growth-positive
Galimedix Therapeutics, Inc.'s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen's Aducanumab
Galimedix Therapeutics, Inc. announced that the recent positive results of a Phase 3 study in Alzheimer’s disease with Biogen’s aducanumab also validate the target of the company’s lead molecule, GAL-101. GAL-101 has the advantage of being a small molecule and blocks the formation of all forms of toxic oligomers at source while the antibody eliminates them only after their formation. Galimedix considers the recently announced aducanumab results in Alzheimer’s disease to be validation for GAL-101 eyedrops, which target the same amyloid beta pathology in dry macular degeneration (AMD) and glaucoma. The company is developing a Phase 2 program in these two indications using GAL-101 eyedrops. An additional oral formulation of GAL-101 is also in development for Alzheimers disease.
PartnersInvestment
growth-positive
Preclinical Studies Demonstrate Galimedix Therapeutics' Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models
Galimedix Therapeutics, a company developing solutions for ophthalmic and neurodegenerative diseases, has presented data showing that its investigational compound GAL-101 provides neuroprotection from misfolded amyloid beta molecules. The compound may also provide sustained detoxification. The data was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The companys Chief Scientific Officer, Dr. Hermann Russ, commented that the unique mechanism of GAL-101 has been shown to reduce the levels of amyloid beta present in the retina, thereby preventing neurodegeneration and increasing the chances of preventing vision loss.
InvestmentExpand
growth-positive
Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference
Galimedix Therapeutics presented an overview of data on its compound GAL-101, which has shown potential in preventing the formation of toxic amyloid beta oligomers in ophthalmic diseases. The company also presented positive safety and tolerability data from its Phase 1 study. GAL-101 was shown to reach the retina quickly and have a sustained effect for weeks. Galimedix is currently planning and fundraising for a Phase 2 program. The company is a phase 2 ophthalmic pharmaceutical company with a novel drug addressing glaucoma and dry AMD using an eye drops delivery platform.
InvestmentExpand
growth-positive
Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer
Galimedix Therapeutics has appointed Hermann Russ, M.D., Ph.D., as its chief scientific officer. Dr. Russ is an expert in the field of neurodegenerative diseases and has knowledge of the companys lead molecule for the treatment of degenerative diseases of the retina. His appointment is expected to contribute to the development of the company and bring a new treatment to patients suffering from degenerative diseases. Galimedix is a phase 2 ophthalmic pharmaceutical company that focuses on developing solutions for ophthalmic and neurodegenerative diseases. The companys novel drug, GAL-101, is delivered through eye drops and has shown promising results in animal models. Galimedix holds an exclusive worldwide license from Tel Aviv University for the drug.
Management Changes
growth-positive
Galimedix Therapeutics, Inc. To Present at the BIO Investor Summit
Galimedix Therapeutics, Inc.s chief scientific officer will present and meet with investors at the BIO Investor Summit. The company is a Phase 2/3-ready ophthalmic pharmaceutical company developing a novel drug for glaucoma and dry AMD. Their most advanced compound, GAL-101, has shown promising results in animal models and has completed Phase 1 studies. The company is supported by leading experts in the field and is also exploring oral delivery of the drug. The announcement of the presentation at the BIO Investor Summit suggests positive growth opportunities for the company.
InvestmentManagement Changes
Galimedix Therapeutics Team
Christopher Parsons
Co-Founder, Chief Pharmacologist & VP of Non-Clinical Development
Founder
Employee Info
| Employees (range) | 1-10 |
| Exact count | 10 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Galimedix Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 515669174 |
| Crunchbase | galimedix-therapeutics |
| Phone | +97249905139 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-05-28T00:00:00.000Z |
| Created | 2019-11-07T00:00:00.000Z |